Evidence map›Paper›PMID 39802196›Full record

ArticleTransplantation direct2025

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?

Ahmed Alnughmush, Ayman Sayyed, Mats Remberger, Eshrak Al-Shaibani, Carol Chen, Caden Chiarello, Ivan Pasic, Igor Novitzky-Basso, Arjun Datt Law, Wilson Lam and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ahmed AlnughmushDepartment of Medicine, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0001-8489-0642
Ayman SayyedDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Mats RembergerKFUE, Uppsala University Hospital, and IMV, Uppsala University, Uppsala, Sweden.
Eshrak Al-ShaibaniDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Carol ChenHans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Caden ChiarelloHans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ivan PasicDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Igor Novitzky-BassoDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Arjun Datt LawDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Wilson LamDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Dennis Dong Hwan KimDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Armin GerbitzDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Auro ViswabandyaDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Rajat KumarDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Fotios V MichelisDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Jonas MattssonDepartment of Medicine, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite decades of post-allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been challenged in numerous studies. Methods: In this retrospective cohort study conducted at the Princess Margaret Cancer Centre, we analyzed the clinical outcomes of 509 patients who underwent allogeneic HCT between May 1, 2019, and May 31, 2022. This study aimed to assess the impact of granulocyte colony-stimulating factor (G-CSF) administration posttransplantation on neutrophil and platelet engraftment, incidence of bloodstream infections (BSIs), graft-versus-host disease, engraftment syndrome (ES), and survival metrics including overall survival, nonrelapse mortality, and graft-versus-host disease-free/relapse-free survival. Results: Our findings indicate that G-CSF administration expedited neutrophil engraftment (16 versus 18 d, Conclusions: Although G-CSF post-HCT expedited neutrophil engraftment and reduced BSI risk, it did not result in a survival advantage. The association with ES necessitates careful consideration.

Identifiers

PMID39802196
PMCPMC11723673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.